Compare Amphastar Pharmaceuticals Inc (AMPH) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Roundhill Magnificent Seven ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Roundhill Magnificent Seven ETF trades at $67.52. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MAGS | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $70.94 |
52-Week Low | $16.87 | $55.39 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MAGS trades at $67.68, up 1.38% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF holds equal-weighted Magnificent Seven stocks, offering concentrated mega-cap tech exposure. Recent news highlights AI-driven volatility and debates over concentration risks versus growth potential, with the fund up 181% since launch but facing 2026 headwinds as AI profits outside tech remain uncertain.
Outlook hinges on AI adoption and interest rate trends, with small-cap rotation posing a risk. Opportunities include hyperscaler valuation compression and quarterly rebalancing. Key risks are overconcentration in tech, regulatory scrutiny, and macroeconomic shifts affecting growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
